Genetic variants and risk of lung cancer in never smokers

A genome-wide association study

Yafei Li, Chau Chyun Sheu, Yuanqing Ye, Mariza De Andrade, Liang Wang, Shen Chih Chang, Marie C. Aubry, Jeremiah A. Aakre, Mark S. Allen, Feng Chen, Julie M Cunningham, Claude Deschamps, Ruoxiang Jiang, Jie Lin, Randolph Stuart Marks, V. Shane Pankratz, Li Su, Yan Li, Zhifu D Sun, Hui Tang & 9 others George Vasmatzis, Curtis C. Harris, Margaret R. Spitz, Jin Jen, Renyi Wang, Zuo Feng Zhang, David C. Christiani, Xifeng Wu, Ping Yang

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Background: Lung cancer in individuals who have never smoked tobacco products is an increasing medical and public-health issue. We aimed to unravel the genetic basis of lung cancer in never smokers. Methods: We did a four-stage investigation. First, a genome-wide association study of single nucleotide polymorphisms (SNPs) was done with 754 never smokers (377 matched case-control pairs at Mayo Clinic, Rochester, MN, USA). Second, the top candidate SNPs from the first study were validated in two independent studies among 735 (MD Anderson Cancer Center, Houston, TX, USA) and 253 (Harvard University, Boston, MA, USA) never smokers. Third, further replication of the top SNP was done in 530 never smokers (UCLA, Los Angeles, CA, USA). Fourth, expression quantitative trait loci (eQTL) and gene-expression differences were analysed to further elucidate the causal relation between the validated SNPs and the risk of lung cancer in never smokers. Findings: 44 top candidate SNPs were identified that might alter the risk of lung cancer in never smokers. rs2352028 at chromosome 13q31.3 was subsequently replicated with an additive genetic model in the four independent studies, with a combined odds ratio of 1·46 (95% CI 1·26-1·70, p=5·94×10-6). A cis eQTL analysis showed there was a strong correlation between genotypes of the replicated SNPs and the transcription level of the gene GPC5 in normal lung tissues (p=1·96×10-4), with the high-risk allele linked with lower expression. Additionally, the transcription level of GPC5 in normal lung tissue was twice that detected in matched lung adenocarcinoma tissue (p=6·75×10-11). Interpretation: Genetic variants at 13q31.3 alter the expression of GPC5, and are associated with susceptibility to lung cancer in never smokers. Downregulation of GPC5 might contribute to the development of lung cancer in never smokers. Funding: US National Institutes of Health; Mayo Foundation.

Original languageEnglish (US)
Pages (from-to)321-330
Number of pages10
JournalThe Lancet Oncology
Volume11
Issue number4
DOIs
StatePublished - Apr 2010

Fingerprint

Genome-Wide Association Study
Single Nucleotide Polymorphism
Lung Neoplasms
Quantitative Trait Loci
Lung
Los Angeles
Genetic Models
National Institutes of Health (U.S.)
Tobacco Products
Down-Regulation
Public Health
Chromosomes
Alleles
Odds Ratio
Genotype
Gene Expression
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Genetic variants and risk of lung cancer in never smokers : A genome-wide association study. / Li, Yafei; Sheu, Chau Chyun; Ye, Yuanqing; De Andrade, Mariza; Wang, Liang; Chang, Shen Chih; Aubry, Marie C.; Aakre, Jeremiah A.; Allen, Mark S.; Chen, Feng; Cunningham, Julie M; Deschamps, Claude; Jiang, Ruoxiang; Lin, Jie; Marks, Randolph Stuart; Pankratz, V. Shane; Su, Li; Li, Yan; Sun, Zhifu D; Tang, Hui; Vasmatzis, George; Harris, Curtis C.; Spitz, Margaret R.; Jen, Jin; Wang, Renyi; Zhang, Zuo Feng; Christiani, David C.; Wu, Xifeng; Yang, Ping.

In: The Lancet Oncology, Vol. 11, No. 4, 04.2010, p. 321-330.

Research output: Contribution to journalArticle

Li, Y, Sheu, CC, Ye, Y, De Andrade, M, Wang, L, Chang, SC, Aubry, MC, Aakre, JA, Allen, MS, Chen, F, Cunningham, JM, Deschamps, C, Jiang, R, Lin, J, Marks, RS, Pankratz, VS, Su, L, Li, Y, Sun, ZD, Tang, H, Vasmatzis, G, Harris, CC, Spitz, MR, Jen, J, Wang, R, Zhang, ZF, Christiani, DC, Wu, X & Yang, P 2010, 'Genetic variants and risk of lung cancer in never smokers: A genome-wide association study', The Lancet Oncology, vol. 11, no. 4, pp. 321-330. https://doi.org/10.1016/S1470-2045(10)70042-5
Li, Yafei ; Sheu, Chau Chyun ; Ye, Yuanqing ; De Andrade, Mariza ; Wang, Liang ; Chang, Shen Chih ; Aubry, Marie C. ; Aakre, Jeremiah A. ; Allen, Mark S. ; Chen, Feng ; Cunningham, Julie M ; Deschamps, Claude ; Jiang, Ruoxiang ; Lin, Jie ; Marks, Randolph Stuart ; Pankratz, V. Shane ; Su, Li ; Li, Yan ; Sun, Zhifu D ; Tang, Hui ; Vasmatzis, George ; Harris, Curtis C. ; Spitz, Margaret R. ; Jen, Jin ; Wang, Renyi ; Zhang, Zuo Feng ; Christiani, David C. ; Wu, Xifeng ; Yang, Ping. / Genetic variants and risk of lung cancer in never smokers : A genome-wide association study. In: The Lancet Oncology. 2010 ; Vol. 11, No. 4. pp. 321-330.
@article{1927a475672e4a07ba4c4d4eb96c5a2c,
title = "Genetic variants and risk of lung cancer in never smokers: A genome-wide association study",
abstract = "Background: Lung cancer in individuals who have never smoked tobacco products is an increasing medical and public-health issue. We aimed to unravel the genetic basis of lung cancer in never smokers. Methods: We did a four-stage investigation. First, a genome-wide association study of single nucleotide polymorphisms (SNPs) was done with 754 never smokers (377 matched case-control pairs at Mayo Clinic, Rochester, MN, USA). Second, the top candidate SNPs from the first study were validated in two independent studies among 735 (MD Anderson Cancer Center, Houston, TX, USA) and 253 (Harvard University, Boston, MA, USA) never smokers. Third, further replication of the top SNP was done in 530 never smokers (UCLA, Los Angeles, CA, USA). Fourth, expression quantitative trait loci (eQTL) and gene-expression differences were analysed to further elucidate the causal relation between the validated SNPs and the risk of lung cancer in never smokers. Findings: 44 top candidate SNPs were identified that might alter the risk of lung cancer in never smokers. rs2352028 at chromosome 13q31.3 was subsequently replicated with an additive genetic model in the four independent studies, with a combined odds ratio of 1·46 (95{\%} CI 1·26-1·70, p=5·94×10-6). A cis eQTL analysis showed there was a strong correlation between genotypes of the replicated SNPs and the transcription level of the gene GPC5 in normal lung tissues (p=1·96×10-4), with the high-risk allele linked with lower expression. Additionally, the transcription level of GPC5 in normal lung tissue was twice that detected in matched lung adenocarcinoma tissue (p=6·75×10-11). Interpretation: Genetic variants at 13q31.3 alter the expression of GPC5, and are associated with susceptibility to lung cancer in never smokers. Downregulation of GPC5 might contribute to the development of lung cancer in never smokers. Funding: US National Institutes of Health; Mayo Foundation.",
author = "Yafei Li and Sheu, {Chau Chyun} and Yuanqing Ye and {De Andrade}, Mariza and Liang Wang and Chang, {Shen Chih} and Aubry, {Marie C.} and Aakre, {Jeremiah A.} and Allen, {Mark S.} and Feng Chen and Cunningham, {Julie M} and Claude Deschamps and Ruoxiang Jiang and Jie Lin and Marks, {Randolph Stuart} and Pankratz, {V. Shane} and Li Su and Yan Li and Sun, {Zhifu D} and Hui Tang and George Vasmatzis and Harris, {Curtis C.} and Spitz, {Margaret R.} and Jin Jen and Renyi Wang and Zhang, {Zuo Feng} and Christiani, {David C.} and Xifeng Wu and Ping Yang",
year = "2010",
month = "4",
doi = "10.1016/S1470-2045(10)70042-5",
language = "English (US)",
volume = "11",
pages = "321--330",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - Genetic variants and risk of lung cancer in never smokers

T2 - A genome-wide association study

AU - Li, Yafei

AU - Sheu, Chau Chyun

AU - Ye, Yuanqing

AU - De Andrade, Mariza

AU - Wang, Liang

AU - Chang, Shen Chih

AU - Aubry, Marie C.

AU - Aakre, Jeremiah A.

AU - Allen, Mark S.

AU - Chen, Feng

AU - Cunningham, Julie M

AU - Deschamps, Claude

AU - Jiang, Ruoxiang

AU - Lin, Jie

AU - Marks, Randolph Stuart

AU - Pankratz, V. Shane

AU - Su, Li

AU - Li, Yan

AU - Sun, Zhifu D

AU - Tang, Hui

AU - Vasmatzis, George

AU - Harris, Curtis C.

AU - Spitz, Margaret R.

AU - Jen, Jin

AU - Wang, Renyi

AU - Zhang, Zuo Feng

AU - Christiani, David C.

AU - Wu, Xifeng

AU - Yang, Ping

PY - 2010/4

Y1 - 2010/4

N2 - Background: Lung cancer in individuals who have never smoked tobacco products is an increasing medical and public-health issue. We aimed to unravel the genetic basis of lung cancer in never smokers. Methods: We did a four-stage investigation. First, a genome-wide association study of single nucleotide polymorphisms (SNPs) was done with 754 never smokers (377 matched case-control pairs at Mayo Clinic, Rochester, MN, USA). Second, the top candidate SNPs from the first study were validated in two independent studies among 735 (MD Anderson Cancer Center, Houston, TX, USA) and 253 (Harvard University, Boston, MA, USA) never smokers. Third, further replication of the top SNP was done in 530 never smokers (UCLA, Los Angeles, CA, USA). Fourth, expression quantitative trait loci (eQTL) and gene-expression differences were analysed to further elucidate the causal relation between the validated SNPs and the risk of lung cancer in never smokers. Findings: 44 top candidate SNPs were identified that might alter the risk of lung cancer in never smokers. rs2352028 at chromosome 13q31.3 was subsequently replicated with an additive genetic model in the four independent studies, with a combined odds ratio of 1·46 (95% CI 1·26-1·70, p=5·94×10-6). A cis eQTL analysis showed there was a strong correlation between genotypes of the replicated SNPs and the transcription level of the gene GPC5 in normal lung tissues (p=1·96×10-4), with the high-risk allele linked with lower expression. Additionally, the transcription level of GPC5 in normal lung tissue was twice that detected in matched lung adenocarcinoma tissue (p=6·75×10-11). Interpretation: Genetic variants at 13q31.3 alter the expression of GPC5, and are associated with susceptibility to lung cancer in never smokers. Downregulation of GPC5 might contribute to the development of lung cancer in never smokers. Funding: US National Institutes of Health; Mayo Foundation.

AB - Background: Lung cancer in individuals who have never smoked tobacco products is an increasing medical and public-health issue. We aimed to unravel the genetic basis of lung cancer in never smokers. Methods: We did a four-stage investigation. First, a genome-wide association study of single nucleotide polymorphisms (SNPs) was done with 754 never smokers (377 matched case-control pairs at Mayo Clinic, Rochester, MN, USA). Second, the top candidate SNPs from the first study were validated in two independent studies among 735 (MD Anderson Cancer Center, Houston, TX, USA) and 253 (Harvard University, Boston, MA, USA) never smokers. Third, further replication of the top SNP was done in 530 never smokers (UCLA, Los Angeles, CA, USA). Fourth, expression quantitative trait loci (eQTL) and gene-expression differences were analysed to further elucidate the causal relation between the validated SNPs and the risk of lung cancer in never smokers. Findings: 44 top candidate SNPs were identified that might alter the risk of lung cancer in never smokers. rs2352028 at chromosome 13q31.3 was subsequently replicated with an additive genetic model in the four independent studies, with a combined odds ratio of 1·46 (95% CI 1·26-1·70, p=5·94×10-6). A cis eQTL analysis showed there was a strong correlation between genotypes of the replicated SNPs and the transcription level of the gene GPC5 in normal lung tissues (p=1·96×10-4), with the high-risk allele linked with lower expression. Additionally, the transcription level of GPC5 in normal lung tissue was twice that detected in matched lung adenocarcinoma tissue (p=6·75×10-11). Interpretation: Genetic variants at 13q31.3 alter the expression of GPC5, and are associated with susceptibility to lung cancer in never smokers. Downregulation of GPC5 might contribute to the development of lung cancer in never smokers. Funding: US National Institutes of Health; Mayo Foundation.

UR - http://www.scopus.com/inward/record.url?scp=77950341944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950341944&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(10)70042-5

DO - 10.1016/S1470-2045(10)70042-5

M3 - Article

VL - 11

SP - 321

EP - 330

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -